Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016 2017 2018

Details for Mechanism ID: 18050
Country/Region: Haiti
Year: 2016
Main Partner: Centers for Development and Health
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $1,125,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $100,593
Care: TB/HIV (HVTB) $77,807
Care: Pediatric Care and Support (PDCS) $89,951
Strategic Information (HVSI) $33,528
Testing: HIV Testing and Counseling (HVCT) $128,445
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $137,444
Treatment: Adult Treatment (HTXS) $514,811
Treatment: Pediatric Treatment (PDTX) $42,421
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 9
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 9
GEND_GBV Number of people receiving post-GBV care 2017 9
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 749
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 749
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 9,604
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 6,953
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 18,055
HTS_TST Service Delivery Point (Facility): Pediatric 2017 1,496
HTS_TST Service Delivery Point (Facility): PMTCT 2017 6,402
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 195
HTS_TST Service Delivery Point (Facility): VCT 2017 9,962
HTS_TST Sum of Aggregated Age/Sex <15 2017 1,498
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 16,557
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 18,055
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 13
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 13
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 152
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 107
PMTCT_ART Already on ART at beginning of current pregnancy 2017 33
PMTCT_ART New on ART 2017 92
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 6,402
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 78
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 47
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 3
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 4
PMTCT_EID Sum of Infant Age disaggregates 2017 125
PMTCT_STAT By: Known positives at entry 2017 40
PMTCT_STAT By: Number of new positives identified 2017 90
PMTCT_STAT Number of new ANC and L&D clients 2017 6,715
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 6,402
PMTCT_STAT Sum of Positives Status disaggregates 2017 130
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 22
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 18
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 40
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 40
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 28
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 8
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 28
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 5
TB_SCREENDX Screen Result: Screened Positive for TB 2017 28
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 729
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 484
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 34
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 24
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 1,271
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 5
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 113
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 5
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 72
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 195
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 327
TX_CURR Aggregated Age/Sex: <15 Female 2017 34
TX_CURR Aggregated Age/Sex: <15 Male 2017 24
TX_CURR Aggregated Age/Sex: 15+ Female 2017 729
TX_CURR Aggregated Age/Sex: 15+ Male 2017 484
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 1,271
TX_CURR Sum of Aggregated Age/Sex <15 2017 58
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 1,213
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 1,271
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 9
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 9
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 196
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 143
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 357
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 357
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 1,271
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 952
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 25
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 17
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 546
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 364
TX_PVLS Numerator: Indication: Routine 2017 858
TX_PVLS Numerator: Indication: Targeted 2017 94
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 34
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 24
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 729
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 484
TX_PVLS_den Denominator: Indication: Routine 2017 1,144
TX_PVLS_den Denominator: Indication: Targeted 2017 127
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 9
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 7
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 197
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 116
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 329
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 432
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 13
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 9
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 259
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 151
Cross Cutting Budget Categories and Known Amounts Total: $615,000
Motor Vehicles: Purchased $55,000
Human Resources for Health $500,000
Gender: Gender Based Violence (GBV) $25,000
Post GBV Care
Implementation
Capacity building
Gender: Gender Equality $35,000
Increase gender-equitable access to income and productive resources, including education